Vonoprazan/amoxicillin/clarithromycin

Last updated

Vonoprazan/amoxicillin/clarithromycin
VONOSAP Pack 400.jpg
Combination of
Vonoprazan Potassium-competitive acid blocker
Amoxicillin Beta-lactam antibiotic
Clarithromycin Macrolide antibiotic
Clinical data
Trade names Vonosap, Voquezna Triple Pak
License data
ATC code
Legal status
Legal status
Identifiers
KEGG

Vonoprazan/amoxicillin/clarithromycin, sold under the brand name Vonosap among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection. [1] [4] It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker; amoxicillin, a beta-lactam antibiotic; and clarithromycin, a macrolide antibiotic. [1] [4]

Contents

It was approved for medical use in Japan in 2016, [3] and in the United States in May 2022. [1] [2] [5] [6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7] [8]

References

  1. 1 2 3 4 "Voquezna Dual Pak- vonoprazan fumarate and amoxicillin kit Voquezna Triple Pak- vonoprazan fumarate, amoxicillin and clarithromycin kit". DailyMed. U.S. National Library of Medicine. 21 June 2022. Archived from the original on 3 July 2022. Retrieved 3 July 2022.
  2. 1 2 "Phathom Pharmaceuticals Announces FDA Approval of Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults" (Press release). Phathom Pharmaceuticals. 3 May 2022. Archived from the original on 10 May 2022. Retrieved 9 May 2022– via GlobeNewswire.
  3. 1 2 "Vonosap pack 400, Vonosap pack 800 and Vonopion pack (triple-drug blister packs containing Takecab tablet) Now Available for Helicobacter pylori[*] Eradication in Japan". Takeda. 7 June 2016. Archived from the original on 10 May 2022. Retrieved 9 May 2022.
  4. 1 2 Deguchi H, Yamazaki H, Kamitani T, Yamamoto Y, Fukuhara S (July 2021). "Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis". Advances in Therapy. 38 (7): 3937–3947. doi:10.1007/s12325-021-01784-w. PMC   8280045 . PMID   34091865.
  5. ↑ "FDA NDA approval" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 12 May 2022. Retrieved 12 May 2022.
  6. ↑ "Voquezna Triple Pak (amoxicillin, clarithromycin, and vonoprazan) FDA Approval History". Drugs.com.
  7. ↑ "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 10 January 2023. Retrieved 22 January 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  8. ↑ New Drug Therapy Approvals 2022. U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original (PDF) on 14 January 2024. Retrieved 14 January 2024.PD-icon.svg This article incorporates text from this source, which is in the public domain .

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.